Summary
The pharmacokinetics of tenoxicam after a single oral dose of 20 mg has been studied in 12 patients with various degrees of decreased renal function. Unchanged tenoxicam and its 5′OH-metabolite in plasma and urine were determined by HPLC. The mean areas under the plasma concentration-time curve (138±53 µg/ml·h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam. The half-life of 5′OH-tenoxicam and unchanged tenoxicam where the same. The urinary excretion of 5′OH-tenoxicam fell with decreasing renal function. Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wiseman EH, Lombardino JG (1981) A novel family of nonsteroidal anti-inflammatory drugs. Eur J Rheumatol Inflamm 4: 280–297
Heintz RC, Guentert TW, Enrico JF, Dubach UC, Brandt R, Jeunet FS (1985) Pharmacokinetics of tenoxicam in healthy human volunteers. Eur J Rheumatol Inflamm (in press)
Hobbs DC (1983) Pharmacokinetics of piroxicam in man. Eur J Rheumatol Inflamm 6: 46–55
Kölle EU, Hengy H, Vollmer KO (1983) Pharmacokinetics of isoxicam in man following oral administration. Arzneimittelforsch/Drug Res 33: 3–7
Gibson TP, Atkinson AJ, Matusik E, Nelson LD, Biggs WA (1977) Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney Int 12: 422–429
Verbeeck R, Tjandramaga TB, Mullie A, Verbesselt R, Verberckmoes R, De Schepper PJ (1979) Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency. Br J Clin Pharmacol 7: 273–282
Horber FF, Zimmermann A, Frey FJ (1984) Impaired renal function and hypercalcaemia associated with etretinate. Lancet 2: 1093
Heizmann P, Körner J, Zinapold K (1985) Determination of tenoxicam in human plasma by HPLC. J Chromatogr (in press)
Dell D, Joly R, Meister W, Arnold W, Partos C, Guldimann B (1984) The determination of tenoxicam, and the isolation, identification, and determination of Ro 17-6661, its major metabolite, in human urine. J Chromatogr 317: 483–487
Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York, pp 293
Dupont D, Dayer P, Balant L, Gorgia A, Fabre J (1982) Variations inter- et intraindividuelles du comportement du piroxicam. Pharmacocinétique chez l'homme en bonne santé et chez le malade en insuffisance rénale. Pharm Acta Helv 57: 20–26
Moulds RFW (1984) The pharmacokinetics of isoxicam in renal insufficiency. 5th SEAPAL Congress of Rheumatology, Bangkok
Anttila M, Haataja M, Kasanen A (1980) Pharmacokinetics of naproxen in subjects with normal and impaired renal function. Eur J Clin Pharmacol 18: 263–268
Leber HW, Schütterle G (1972) Oxidative drug metabolism in liver microsomes from uremic rats. Kidney Int 2: 152–158
Leber HW, Gleumes L, Schütterle G (1978) Enzyme induction in the uremic liver. Kidney Int 13 (Suppl 8): S-43–-S-48
Mezey E, Tobon F (1971) Rates of ethanol clearance and activities of the ethanol-oxidizing enzymes in chronic alcoholic patients. Gastroenterology 61: 707–715
Tygstrup N (1966) Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scand J Clin Lab Invest 18 (Suppl 92): 118–125
Simon LS, Mills JA (1980) Nonsteroidal antiinflammatory drugs. NEJM 22: 1237–1243
Verbeeck RK, Blackburn JL, Loewen GR (1983) Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinetics 8: 297–331
Laederach K (1984) Renale Toxizität der Entzündungshemmer. Pharmakritik 9: 33–36
Stierlin H, Faigle JW, Colombi A (1978) Pharmacokinetics of diclofenac sodium (Voltaren) and metabolites in patients with impaired renal function. Scand J Rheumatol Suppl 22: 30–35
Stein G, Kunze M, Zaumseil J, Traeger A (1977) Zur Pharmakokinetik von Indomethazin and Indomethazinmetaboliten bei wiederholter Applikation an nierengesunden und nierengeschädigten Patienten. Int J Clin Pharmacol 15: 470–473
Stafanger G, Larsen HW, Hansen H, Sørensen K (1981) Pharmacokinetics of ketoprofen in patients with chronic renal failure. Scand J Rheumatol 10: 189–192
Wibell L, Nilsson P, Lindström B (1981) Kinetics of indoprofen in patients with renal insufficiency (preliminary report). Eur J Rheumatol Inflamm 4: 16–21
Traeger A, Stein G, Kunze M, Zaumseil J (1972) Zur Pharmakokinetik von Indomethazin bei nierengeschädigten Patienten. Int J Clin Pharmacol 6: 237–242
Held H (1979) Eliminationshalbwertszeiten und Serumproteinbindung des Antirheumatikums Naproxen bei Niereninsuffizienz. Z Rheumatol 38: 111–119
Cuisinaud G, Legheand J, Llorca G, Belkahia C, Lejeune E, Sassard J (1979) Pharmacokinetics of fenbufen in man. Eur J Clin Pharmacol 16: 59–61
Rogers HJ, Savitsky JP, Glenn B, Spector RG (1981) Kinetics of single doses of fenbufen in patients with renal insufficiency. Clin Pharmacol Ther 29: 74–80
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Horber, F.F., Guentert, T.W., Weidekamm, E. et al. Pharmacokinetics of tenoxicam in patients with impaired renal function. Eur J Clin Pharmacol 29, 697–701 (1986). https://doi.org/10.1007/BF00615961
Issue Date:
DOI: https://doi.org/10.1007/BF00615961